A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Read time: 2 mins
Last updated:1st Jul 2012
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
|Date last updated at source||2016-08-27|
|Study start date||2012-07-01|
|Estimated primary completion date||2019-08-01|